Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Relapsed Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia
About this trial
This is an interventional treatment trial for Relapsed Acute Promyelocytic Leukemia focused on measuring relapsed, acute promyelocytic leukemia, arsenic
Eligibility Criteria
Inclusion Criteria: Patients in first or subsequent hematological or molecular relapse of APL Persistence of a positive PCR or no hematological complete remission (CR) after first line therapy No complete hematological remission after first line therapy Age over 18 years No upper age limit Informed consent of the patient Exclusion Criteria: Absolute QTc-interval prolonged over 460 msec before therapy (normal electrolytes, no other drugs prolonging the QT-interval) Heart failure New York Health Association grade III and IV Renal or hepatic failure World Health Organization grade >= III Pneumonia with hypoxemia Uncontrolled sepsis Pregnancy and lactation period Secondary malignancy, which will have major influence on the prognosis Expected noncompliance No informed consent of the patient.
Sites / Locations
- Eva Lengfelder, MD, PhDRecruiting